NCT01509742View on ClinicalTrials.gov

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

November 30, 2001

Study Completion Date

November 30, 2001

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

DRUG

placebo

Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

Trial Locations (1)

37431

Novo Nordisk Investigational Site, Bad Lauterberg im Harz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY